Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis
https://doi.org/10.21518/2079-701X-2021-5-113-123
Abstract
Introduction. Treatment of patients with ulcerative colitis (UC) requires continuous anti-relapse therapy. Mesalazines are the firstline disease-modifying drugs for the treatment of mild to moderate UC to manage exacerbations and to induce and maintain remission.
This paper is aimed at comparing the efficacy of treatment of patients with pancolitis and left-sided ulcerative colitis of moderate severity, who received MMX mesalazine as monotherapy and MMX mesalazine combined with mesalazines in the form of microclysters and suppositories.
Materials and methods. A comparative clinical evaluation of the outcomes of treatment of patients with moderate UC who received MMX mesalazine as monotherapy (group 1) and MMX mesalazine combined with topical mesalazine (microclysters, suppositories) (group 2) was carried out. 40 patients with UC (group 1) and 46 (group 2) were examined.
Results and discussion. Two weeks after MMX mesalazine therapy initiation, 92.8% of patients in group 1 responded to MMX mesalazine therapy and continued using the drugs as monotherapy (without microclysters and suppositories). In group 1, 95.6% of patients responded to MMX mesalazine therapy and continued treatment with topical mesalazines (microclysters and suppositories). At week 12, 54.3% of 35 patients in group 1, who responded to MMX mesalazine therapy, achieved clinical remission, 45.7% achieved clinical endoscopic remission. The Mayo Score decreased from 8.0 ± 0.17 to 2.3 ± 0.3 points. At week 12, 57.1% of patients with UC in group 2, who responded to MMX mesalazine therapy, achieved clinical remission, and 42.9% achieved clinical and endoscopic remission. The Mayo Score decreased from 7.85 ± 0.14 to 2.4 ± 0.3 points. There was no statistically significant difference in the level of laboratory findings between the groups of patients at 12 weeks and at 52 weeks (p> 0.05).
Conclusion. The long-term continuous administration of MMX mesalazine in patients with pancolitis and left-sided ulcerative colitis of moderate severity as monotherapy during the year is comparable in its efficacy with combined MMX mesalazine therapy and topical forms of mesalazine.
About the Authors
O. V. Knyazev
Moscow Clinical Scientific Center named after A.S. Loginov;
Research Institute of Health Organization and Medical Management;
Ryzhikh State Scientific Center of Coloproctology
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Head of the Department of Treatment of Inflammatory Bowel Diseases, 86, Shosse Entuziastov, Moscow, 111123;
Specialist of the Department of Coloproctology, 30, Bolshaya Tatarskaya St., Moscow, 115184;
Professor of the Scientific and Еducational Department, 2, Salyam Adil St., Moscow, 123423
A. V. Kagramanova
Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Russian Federation
Cand. Sci. (Med.), Senior Research Associate,
86, Shosse Entuziastov, Moscow, 111123
A. A. Lishchinskaya
Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Russian Federation
Cand. Sci. (Med.), Senior Research Associate,
86, Shosse Entuziastov, Moscow, 111123
References
1. Khatkov I.E., Parfenov A.I., Knyazev O.V., Mikhaylyants G.S., Atroshchenko A.O., Ruchkina I.N. Inflammatory bowel diseases in the therapeutic and surgical practice. Moscow: Vita-PRESS; 2017. 120 р. (In Russ.) Available at: https://search.rsl.ru/ru/record/01008829975.
2. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi: 10.1016/S0140-6736(17)32448-0.
3. Cohen R.D., Yu A.P., Wu E.Q., Xie J., Mulani P.M., Chao J. Systematic review: The costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31(7):693–707. doi: 10.1111/j.1365-2036.2010.04234.x.
4. Baghaei A., Emami M.H., Adibi P., Tavakkoli H., Daghaghzadeh H., Tamizifar B. et al. Inflammatory Bowel Disease Registry and Monitoring: Feasibility Study and Application (Isfahan Inflammatory Bowel Disease Surveillance Project). Int J Prev Med. 2019;10:190. doi: 10.4103/ijpvm.IJPVM_316_17.
5. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(SA):5A–36A. doi: 10.1155/2005/269076.
6. Burisch J., Jess T., Martinato M., Lakatos P.L.; ECCO-EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4): 322–337. doi: 10.1016/j.crohns.2013.01.010.
7. Jess T., Riis L., Vind I., Winther K.V., Borg S., Binder V. et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13(4):481–489. doi: 10.1002/ibd.20036.
8. Russel M.G., Dorant E., Volovics A., Brummer R.J., Pop P., Muris J.W. et al. High incidence of inflammatory bowel disease in the Netherlands: results of a prospective study. The South Limburg IBD Study Group. Dis Colon Rectum. 1998;41(1):33–40. doi: 10.1007/BF02236893.
9. Gower-Rousseau C., Salomez J.L., Dupas J.L., Marti R., Nuttens M.C., Votte A. et al. Incidence of inflammatory bowel disease in northern France (1988–1990). Gut. 1994;35(10):1433–1438. doi: 10.1136/gut.35.10.1433.
10. Bjornsson S., Johansson J.H., Oddsson E. Inflammatory Bowel disease in Iceland, 1980–1989: a retrospective nationwide epidemiologic study. Scand J Gastroenterol. 1998;33(1):71–77. Available at: https://www.hirsla.lsh.is/handle/2336/50073.
11. Henriksen M., Jahnsen J., Lygren I., Sauar J., Kjellevold O., Shulz T. et al.; IBSEN Study Group. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12(7):543–550. doi: 10.1097/01.MIB.0000225339.91484.fc.
12. Moum B., Ekbom A., Vatn M.H., Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol. 1999;94(6):1564–1569. doi: 10.1111/j.1572-0241.1999.01145.x.
13. Ritchie J.K., Powell-Tuck J., Lennard-Jones J.E. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet. 1978;1(8074):1140– 1143. doi: 10.1016/S0140-6736(78)90312-4.
14. Ekbom A., Helmick C., Zack M., Adami H.O. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18):1228–1233. doi: 10.1056/NEJM199011013231802.
15. Belousova E.A., Abdulganieva D.I., Alexeeva O.P., Alexeenko S.A., Baranovsky A.Yu., Valuyskikh E.Yu. et al. Social and demographic characteristics, features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies. Aʹmanakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2018;46(5):445–463. (In Russ.) doi: 10.18786/2072-0505-2018-46-5-445-463.
16. Ivashkin V.T., Shelygin Yu.A., Belousova E.A., Abdulganieva D.I., Alekseeva O.A., Achkasov S.I. et al. Project: clinical guidelines for the diagnostics and treatment of ulcerative colitis. Koloproktologia. 2019;18(4): 7–36. (In Russ.) doi: 10.33878/2073-7556-2019-18-4-7-36.
17. Lichtenstein G.R., Loftus E.V., Isaacs K.L., Regueiro M.D., Gerson L.B., Sands B.E. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018;113(4):481–517. doi: 10.1038/ajg.2018.27.
18. Kornbluth A., Sachar D.B.; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–523. doi: 10.1038/ajg.2009.727.
19. Magro F., Gionchetti P., Eliakim R., Ardizzone S., Armuzzi A., Barrero-de Acosta M. et al.; European Crohn’s and Colitis Organisation (ECCO). Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11(6):649–670. doi: 10.1093/ecco-jcc/jjx008.
20. Gomollón F., Dignass A., Annese V., Tilg H., Van Assche G., Lindsay J.O. et al. ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3–25. doi: 10.1093/ecco-jcc/jjw168.
21. Vorobev G.I., Khalif I.L. (eds.). Nonspecific inflammatory bowel diseases. Мoscow: Miklosh; 2008. 400 p. (In Russ.) Available at: http://kingmed.info/knigi/Gastroenterologiya/book_485/Nespetsificheskie_vospalitelnye_zabolevaniya_kishechnika-Vorobev_GI_Halif_IL-2008-pdf.
22. Belousova E.A., Nikitina N.V., Tsodikova O.M. Treatment of mild to moderate ulcerative colitis. Pharmateca. 2013;(2):42–46. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/8718.
23. Egan L.J., Sandborn W.J. Clinical pharmacology in inflammatory Bowel disease: optimizing current medical therapy. In: Targan S.R., Shanahan F., Karp L.C. (eds.). Inflammatory Bowel Disease: From Bench to Bedside. Springer, Boston, MA. doi: 10.1007/0-387-25808-6_25.
24. Tenjarla S., Abinusawa A. In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness. Adv Ther. 2011;28:62–72. doi: 10.1007/s12325-010-0087-5.
25. Brunner M., Assandri R., Kletter K., Tschurlovits M., Corrado M.E., Villa R. et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther. 2003;17(3): 395–402. doi: 10.1046/j.1365-2036.2003.01445.x.
26. Lachaine J., Yen L., Beauchemin C., Hodgkins P. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterology. 2013;13:23. doi: 10.1186/1471-230X-13-23.
27. Sandborn W.J., Kamm M.A., Lichtenstein G.R., Lyne A., Butler T., Joseph R.E. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007;26(2):205–215. doi: 10.1111/j.1365-2036.2007.03361.x.
28. Kamm M.A., Sandborn W.J., Gassull M., Schreiber S., Jackowski L., Butler T. et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132(1):66–75. doi: 10.1053/j.gastro.2006.10.011.
29. Lily P.H., McCormack P.L. MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis. Drugs. 2011;71(2):221–235. doi: 10.2165/11205870-000000000-00000.
30. Prantera C., Kohn A., Campieri M., Caprilli R., Cottone M., Pallone V. et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther. 2009;30(9):908–918. doi: 10.1111/j.1365-2036.2009.04117.x.
31. Cuomo A., Sgambato D., D’Auria M.V., Miranda A., Ferrante E., Romano M. Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis. Dig Dis. 2018;36(2): 130–135. doi: 10.1159/000485614.
32. Harbord M., Eliakim R., Bettenworth D., Karmiris K., Katsanos K., Kopylov U. et al.; European Crohn’s and Colitis Organisation (ECCO). Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784. doi: 10.1093/ecco-jcc/jjx009.
33. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048. doi: 10.1136/bmj.2.4947.1041.
34. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629. doi: 10.1056/NEJM198712243172603.
35. Ko C.W., Singh S., Feuerstein J.D., Falck-Ytter C., Falck-Ytter Y., Cross R.K.; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mildto-Moderate Ulcerative Colitis. Gastroenterology. 2019;156(3):748–764. doi: 10.1053/j.gastro.2018.12.009.
36. Marshall J.K., Thabane M., Steinhart A.H., Newman J.R., Anand A., Irvine E.J. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115. doi: 10.1002/14651858.CD004115.pub2.
37. Ito H., Matsumoto T., Suzuki Y., Suzuki Y., Sasaki H., Yoshida T. et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16(9):1567–15674. doi: 10.1002/ibd.21193.
38. Nagahori M., Kochi S., Hanai H., Yamamoto T., Nakamura S., Omuro S. et al.; OPTIMUM Study Group. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC Gastroenterol. 2017;17(1):47. doi: 10.1186/s12876- 017-0604-y
Review
For citations:
Knyazev OV, Kagramanova AV, Lishchinskaya AA. Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis. Meditsinskiy sovet = Medical Council. 2021;(5):113-123. (In Russ.) https://doi.org/10.21518/2079-701X-2021-5-113-123
Views:
708
Email this article 